News

CVRX stock gains after Humana adds Medicare Advantage coverage for Barostim therapy, boosting reimbursement momentum and patient access.

Natera wins FDA approval for Signatera CDx in bladder cancer, marking the first blood-based MRD companion diagnostic milestone.

MD gains from stronger cash collections, payer mix and acquisitions, while telehealth expansion and buybacks support growth.

A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining market share, or limited scalability.

Doximity teams with Aledade to bring AI-powered documentation and clinical search tools into physician workflows and value-based care settings.

Revvity gains FDA clearance for IDS' Total Testosterone assay, expanding its automated endocrine testing platform for reproductive diagnostics.

DOCS' revenues top estimates as AI tool adoption and large customer growth fuel engagement despite weaker earnings and margin pressure.

HQY rides on strong HSA growth, AI-driven efficiency gains and solid Q4 results, though data security threats remain a key risk.

The company confirmed data was stolen and encrypted by the attackers.

Veeva Systems expands its medtech reach as Smith+Nephew adopts Veeva Quality Cloud to modernize global quality operations and training.

NeuroPace raises revenue guidance for 2026 after Q1 sales beat estimates and losses narrow, driven by strong RNS System growth.

On May 4, 2026, West Pharmaceutical Services held its annual general meeting, where shareholders voted against a proposal to require an independent board chair policy. This governance outcome comes as the company has recently delivered earnings above consensus expectations, reinforcing the influence of financial performance on investor voting behavior. Against this backdrop of robust recent earnings surprises, we'll examine how the board chair vote outcome may reshape West Pharmaceutical's...